A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification
Study of AZD1775 in Patients with CCNE1 Amplification (Skin Cancer or Melanoma)
Sponsor: National Cancer Institute NCI
Enrolling: Male and Female Patients
IRB Number: AAAS1468
U.S. Govt. ID: NCT03253679
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to determine if we can lower the chance of your cancer growing or spreading with the treatment of AZD1775. We want to find out if this approach is better or worse than the usual approach for your cancer with CCNE1 amplification. The usual approach is defined as care most people get for advanced cancer with CCNE1 amplification.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have advanced solid tumors with a CCNE1 amplification? Yes No
Have you had prior treatment with Wee1 kinase inhibition? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162